Mangalam Drugs And Organics financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹57.1cr−0.4% on Q1 FY26
Net profit
−₹7.6cr−₹13.8 cr in Q1 FY26
EBITDA margin
1.6%+9.4 pts on Q1 FY26
EPS
−₹4.83−₹8.72 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue57.157.3−0.4%
EBITDA0.9−4.5—
EBITDA margin1.6%−7.8%+9.4 pts
Profit before tax−6.7−13.0—
Net profit−7.6−13.8—
EPS−₹4.83−₹8.72—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹57.1 crNet profit₹−7.6 crNet margin−13.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
46.1————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.70.72.60.92.7
10510581.287.968.3
151————
232232318369—
—−27.1%−13.7%——
−9.0−14.935.817.4—
−3.9%−6.4%11.3%4.7%—
−26.8−33.119.22.7—
−38.2−44.46.7−9.1—
−16.5%−19.1%2.1%−2.5%—
−₹24.16−₹28.05₹4.25−₹5.73—
—−760.6%+174.1%——
—4.242.6−11.139.5
—−11.9−20.20.0−27.9
−7.7−7.722.4−11.111.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANGALAM₹29.11

Mangalam Drugs And Organics Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹46.1 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————46.1
- Cash, Equiv & ST Investments2.70.92.60.70.7
+ Total Debt68.387.981.2105.5105.5
Enterprise Value————150.9
Revenue—368.6318.2232.1232.4
Growth %, YoY——-13.7-27.1—
EBITDA—17.435.8-14.9-9.0
Margin %—4.7211.26-6.42-3.87
EBIT—2.719.2-33.1-26.8
Net Income—-9.16.7-44.4-38.2
Margin %—-2.462.11-19.13-16.45
EPS, Adj (current shares)—-5.734.25-28.05-24.16
Growth %, YoY——+174.1-760.6—
Cash from Operations39.5-11.142.64.2—
Capital Expenditures-27.9-0.0-20.2-11.9—
Free Cash Flow11.6-11.122.4-7.7-7.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Mangalam Drugs And Organics financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Mangalam Drugs And Organics (NSE: MANGALAM) had a market capitalisation of ₹46.3 crore at the 29 October 2026 close (₹29.22 a share) and a price-to-book ratio of 0.45. In FY26 its consolidated net loss was ₹44.4 crore on revenue of ₹232 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹7.6 crore. Its debt-to-equity ratio was 1.02 on 31 March 2026. Promoters held 35.65% of the shares on 30 September 2026.

Share price used
₹29.22 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Mangalam Drugs And Organics at a glance · consolidated

Market cap
₹46.3 Crat ₹29.22 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
0.45book value ₹65.11 a share
ROE (FY26)
−35.2%−39.9 pts vs FY25ROCE −22.6%
Debt to equity
1.02net debt ₹105 Cr
Promoter holding
35.65%unchanged vs 30 Jun 202630 September 2026
Net worth
₹103 Cr−30.8% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹7.7 Cr
EPS (FY26)
−₹28.05

Questions

What is the Mangalam Drugs And Organics PE ratio today?

Mangalam Drugs And Organics' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹38.2 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹46.3 crore at ₹29.22 a share.

What is the Mangalam Drugs And Organics PB ratio (price to book value)?

Mangalam Drugs And Organics' price-to-book (PB) ratio is 0.45 at the 29 October 2026 close: a market capitalisation of ₹46.3 crore divided by shareholders' equity (book value) of ₹103 crore on 31 March 2026. That is a book value of ₹65.11 per share against a share price of ₹29.22.

What is the Mangalam Drugs And Organics net worth?

Mangalam Drugs And Organics' net worth — shareholders' equity in its consolidated balance sheet — was ₹103 crore on 31 March 2026, down 30.8% from ₹149 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹46.3 crore at the 29 October 2026 close.

What is the Mangalam Drugs And Organics market cap?

Mangalam Drugs And Organics' market capitalisation was ₹46.3 crore at the 29 October 2026 close: 1.58 crore shares at ₹29.22 each.

Is Mangalam Drugs And Organics debt free?

No. Mangalam Drugs And Organics had borrowings of ₹105 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 1.02. Its cash and current investments were ₹70 lakh, so its net debt was ₹105 crore.

What is the Mangalam Drugs And Organics debt to equity ratio?

Mangalam Drugs And Organics' debt-to-equity ratio was 1.02 on 31 March 2026: borrowings of ₹105 crore against total equity of ₹103 crore. A year earlier, on 31 March 2025, it was 0.54.

What is the Mangalam Drugs And Organics ROE and ROCE?

In FY26, Mangalam Drugs And Organics' return on equity (ROE) was −35.2% and its return on capital employed (ROCE) was −22.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 4.7% and ROCE 11.2%.

What is the Mangalam Drugs And Organics book value per share?

Mangalam Drugs And Organics' book value per share was ₹65.11 on 31 March 2026: shareholders' equity of ₹103 crore divided by the 1.58 crore shares in issue, down 30.8% from ₹94.12 a year earlier. The share price at the 29 October 2026 close was ₹29.22.

What is the Mangalam Drugs And Organics shareholding pattern?

On 30 September 2026, Mangalam Drugs And Organics' shares were held by promoters 35.65%, foreign portfolio investors (FII/FPI) 0.11%, domestic institutions (DII) 0.00% and retail and other non-institutional investors 64.24%. Over the year, FII holding was unchanged and DII holding was unchanged.

What is the Mangalam Drugs And Organics EPS?

Mangalam Drugs And Organics' basic earnings per share (EPS) were −₹28.05 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹24.16.

What is the Mangalam Drugs And Organics revenue and profit in FY26?

In FY26 (April 2025–March 2026), Mangalam Drugs And Organics' consolidated net loss was ₹44.4 crore, against a profit of ₹6.7 crore in FY25, on revenue from operations of ₹232 crore (down 27.1%).

When are the Mangalam Drugs And Organics next results?

Mangalam Drugs And Organics will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Mangalam Drugs And Organics promoter holding?

Promoters held 35.65% of Mangalam Drugs And Organics on 30 September 2026, unchanged from the previous quarter and down 14.65 percentage points from 50.30% a year earlier, according to the shareholding pattern filed with NSE.

What is the Mangalam Drugs And Organics free cash flow?

In FY26, Mangalam Drugs And Organics generated ₹4.2 crore of cash from operations and spent ₹11.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹7.7 crore. In FY25 it was ₹22.4 crore.

What are the Mangalam Drugs And Organics latest quarterly results?

Mangalam Drugs And Organics' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net loss ₹7.6 crore, narrower than the loss of ₹13.8 crore in Q1 FY26; revenue from operations ₹57.1 crore, down 0.4% year on year.

How does Mangalam Drugs And Organics compare with its peers?

On FY26 consolidated figures, against Biofil Chemicals & Pharmaceuticals, Lasa Supergenerics and Vineet Laboratories: Mangalam Drugs And Organics' operating margin of −14.3% is the third highest of the four (Biofil Chemicals & Pharmaceuticals 1.3%, Lasa Supergenerics −136.9%, Vineet Laboratories 10.2%; peer average −41.8%); its return on equity of −35.2% is the third highest of the four (Biofil Chemicals & Pharmaceuticals 13.8%, Lasa Supergenerics −51.1%, Vineet Laboratories 5.3%; peer average −10.7%).

Mangalam Drugs And Organics vs Biofil Chemicals & Pharmaceuticals: how do they compare?

In FY26, Mangalam Drugs And Organics earned net profit of ₹44.4 crore on revenue of ₹232 crore, against ₹2.8 crore on ₹28.4 crore for Biofil Chemicals & Pharmaceuticals. Mangalam Drugs And Organics' operating margin was −14.3% (Biofil Chemicals & Pharmaceuticals 1.3%) and its return on equity −35.2% (Biofil Chemicals & Pharmaceuticals 13.8%). At the 29 October 2026 close, Mangalam Drugs And Organics' market capitalisation was ₹46.3 crore against ₹47.9 crore for Biofil Chemicals & Pharmaceuticals.

Where do these Mangalam Drugs And Organics figures come from?

From Mangalam Drugs And Organics' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.